2-[
18F-FDG
Burkitt lymphoma
Dmax
Lymphoma
Nuclear medicine
PET/CT
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
20 Feb 2024
20 Feb 2024
Historique:
received:
28
12
2023
accepted:
17
02
2024
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
19
2
2024
Statut:
aheadofprint
Résumé
This retrospective study investigated the prognostic role of disease dissemination features (Dmax and Dmax
Identifiants
pubmed: 38374254
doi: 10.1007/s00277-024-05672-5
pii: 10.1007/s00277-024-05672-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443–459
doi: 10.3322/caac.21357
pubmed: 27618563
Roschewski M, Staudt LM, Wilson WH (2022) Burkitt’s lymphoma. N Engl J Med 387(12):1111–1122. https://doi.org/10.1056/NEJMra2025746
doi: 10.1056/NEJMra2025746
pubmed: 36129999
Schmitz R, Young RM, Ceribelli M et al (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490(7418):116–120. https://doi.org/10.1038/nature11378
doi: 10.1038/nature11378
pubmed: 22885699
pmcid: 3609867
Grande BM, Gerhard DS, Jiang A et al (2019) Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood 133(12):1313–1324. https://doi.org/10.1182/blood-2018-09-871418
doi: 10.1182/blood-2018-09-871418
pubmed: 30617194
pmcid: 6428665
Crombie J, LaCasce A (2021) The treatment of Burkitt lymphoma in adults. Blood 137(6):743–750. https://doi.org/10.1182/blood.2019004099
doi: 10.1182/blood.2019004099
pubmed: 33171490
López C, Burkhardt B, Chan JKC et al (2022) Nat Rev Dis Primers 8(1):78. https://doi.org/10.1038/s41572-022-00404-3
doi: 10.1038/s41572-022-00404-3
pubmed: 36522349
Albano D, Bertagna F, Giubbini (2020) R.18F-FDG PET/CT role in Burkitt lymphoma. Clin Transl Imaging 8:39–45
doi: 10.1007/s40336-020-00356-2
Just PA, Fieschi C, Baillet G et al (2008) 18F-fluorodeoxyglucose positron emission tomography/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS 22:695–700
doi: 10.1089/apc.2008.0174
pubmed: 18793085
Zeng W, Lechowicz MJ, Winton E et al (2009) Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med 4:355–358
doi: 10.1097/RLU.0b013e3181a34552
Karantanis D, Durski JM, Lowe VJ et al (2012) 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 75:e68–73
doi: 10.1016/j.ejrad.2009.07.035
Carrillo-Cruz E, Rodrıguez MS, Borrego-Dorado I et al (2015) Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma. Eur J Haematol 94:23–30
doi: 10.1111/ejh.12284
pubmed: 24520874
Albano D, Bosio G, Re A et al (2018) Metabolic behaviour and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt lymphoma: role of Deauville and IHP criteria. Leuk Lymphoma 3:1–8
Wei WX, Huang JJ, Li WY et al (2015) Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma. Chin J Cancer 2(34):608–613
Albano D, Bosio G, Pagani C et al (2019) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging 46:87–96
doi: 10.1007/s00259-018-4173-2
pubmed: 30276438
Cottereau AS, Nioche C, Dirand AS, Clerc J, Morschhauser F, Casasnovas O, Meignan M, Buvat I (2020) 18F-FDG PET dissemination features in diffuse large B-Cell lymphoma are Predictive of Outcome. J Nucl Med 61(1):40–45. https://doi.org/10.2967/jnumed.119.229450
doi: 10.2967/jnumed.119.229450
pubmed: 31201248
pmcid: 6954460
Albano D, Treglia G, Dondi F, Calabrò A, Rizzo A, Annunziata S, Guerra L, Morbelli S, Tucci A, Bertagna F (2023) 18F-FDG PET/CT maximum tumor dissemination (Dmax) in lymphoma: a New Prognostic factor? Cancers (Basel). 15(9):2494. https://doi.org/10.3390/cancers15092494
Hoelzer D, Walewski J, Döhner H, Viardot A, Hiddemann W, Spiekermann K et al (2014) Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 124:3870–3879
doi: 10.1182/blood-2014-03-563627
pubmed: 25359988
pmcid: 4271177
Ferreri AJ, Bruno VM, Donadoni G, Cattaneo C, Fumagalli L, Foppoli M et al (2012) Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. Br J Haematol 159:252–255
doi: 10.1111/bjh.12020
pubmed: 22924636
Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imag 42(2):328–354. https://doi.org/10.1007/s00259-014-2961-x
doi: 10.1007/s00259‐014‐2961‐x
Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. J Clin Oncol 32(27):3059–3067. https://doi.org/10.1200/jco.2013.54.8800
doi: 10.1200/jco.2013.54.8800
pubmed: 25113753
pmcid: 4979083
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Müeller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. ;32:3048–58
Nioche C, Orlhac F, Boughdad S et al (2018) LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res 78(16):4786–4789. https://doi.org/10.1158/0008-5472.CAN-18-0125
doi: 10.1158/0008‐5472.can‐18‐0125
pubmed: 29959149
Dubois D, Dubois EF (1916) A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863–871
doi: 10.1001/archinte.1916.00080130010002
Frood R, Burton C, Tsoumpas C, Frangi AF, Gleeson F, Patel C, Scarsbrook A (2021) Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. Eur J Nucl Med Mol Imaging 48(10):3198–3220. https://doi.org/10.1007/s00259-021-05233-2
doi: 10.1007/s00259-021-05233-2
pubmed: 33604689
pmcid: 8426243
Durmo R, Donati B, Rebaud L, Cottereau AS, Ruffini A, Nizzoli ME, Ciavarella S, Vegliante MC, Nioche C, Meignan M, Merli F, Versari A, Ciarrocchi A, Buvat I, Luminari S (2022) Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: a radio-genomic study. Hematol Oncol 40(4):645–657. https://doi.org/10.1002/hon.3025
doi: 10.1002/hon.3025
pubmed: 35606338
pmcid: 9796042
Cottereau AS, Meignan M, Nioche C, Capobianco N, Clerc J, Chartier L, Vercellino L, Casasnovas O, Thieblemont C, Buvat I (2021) Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. Ann Oncol 32(3):404–411. https://doi.org/10.1016/j.annonc.2020.11.019
doi: 10.1016/j.annonc.2020.11.019
pubmed: 33278600
Bailly C, Eugène T, Couec ML, StrulluM, Frampas E, Campion L et al (2014) Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne) 16(1):54
Wen WX, Huang JJ, Li WY, Zhang X, Xia Y, Jiang WQ et al (2015) Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma. Chin J Cancer 2(34):608–613
Zeng W, Lechowicz MJ, Winton E, Cho SM, Galt JR, Halkar R (2009) Spectrum of FDG PET/CT findings in Burkitt lymphoma. Clin Nucl Med 4:355–358
doi: 10.1097/RLU.0b013e3181a34552
Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E et al (2012) 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 75:e68–73
doi: 10.1016/j.ejrad.2009.07.035